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Dose escalation or intensification by radiation is built on the premise 
that  higher biological doses will lead to better local tumour control. 
Obviously, the ultimate goal should be to obtain uncomplicated cures.  
From a theoretical point of view, both the improvement of techniques 
or the ability to understand the biology of radiation damage to the 
normal tissues resulting in appropriate patient selection and 
pharmacological interventions will increase the therapeutic ratio. 
Radiotherapy techniques have improved dramatically over the last 
decade, now enabling to use IMRT and Volumetric Modulated Arc 
Radiotherapy in daily practice. This results in the possibility to deliver 
high dose radiation in patients that once were deemed to receive 
palliative doses. The on-going developments in on-line adaptation will 
further improve this evolution. Other new developments include dose 
re-distribution studies in which the whole PTV no longer receives an 
homogeneous dose, but a higher dose is delivered on the basis of 
molecular imaging characteristics. In many patients, this allows 
further dose escalation with equal doses to normal tissues. However, 
in the PET-boost study, the mediastinal structures were the most 
frequent dose-limiting (van Elmpt et al; Radiother Oncol 2012). Proton 
therapy has been shown to allow further dose escalation in many 
theoretical planning studies.       
However, knowledge about the biological characteristics of OARs of 
individual patients would allow stratification into risk groups for side 
effects and possibly pharmacological interventions as well. Many 
studies have been reported on the relation between SNPs and side 
effects of radiotherapy. Most results were retrospective and could not 
be replicated in independent prospective validation cohorts (Barnett 
GC et al. Lancet 2012). With better study design and standardisation 
as for instance advocated by the Radiogenomics Consortium, and 
newer techniques such as GWAS, robust genetic features for radiation 
toxicity may emerge (Talbot CJ et al. Br J Cancer 2012).  
In conclusion, dose escalation depends both on optimal techniques 
and biology, but much research remains to be done in order to build 
models and workflows with proven clinical value (Lambin et al. Nat 
Rev Clin Oncol. 2012). 
 
 SYMPOSIUM: RIGHT NOW CAN CLINICAL CHOICES BE 
BASED ON EVIDENCES FROM LARGE DATABASES?  
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Clinical guidelines are recommendations on how healthcare 
professionals should care for people with specific conditions. The 
recommendations are based on the best available evidence. Until 
recently, the highest level of evidence was considered to be derived 
from randomized clinical trials, or even better, meta-analyses of 
randomized clinical trials. Undoubtedly, clinical trials are essential 
but many factors limit their success, such as the costs of long-term 
follow-up, and participants often not being representative of the 
general population. In the last decade, realization that population 
based databases may help in evaluating the generalizability of clinical 
guidelines has emerged. However, one has to be aware of the pitfalls 
of population based databases. Even population-based databases can 
contain a selection bias, and the assumption that the patients in the 
database are a valid representation of the target group should always 
be tested. In addition, the accuracy of the data has to be monitored, 
as well as the setting in which the data have been collected. To make 
optimal use of population-based databases, comorbidity should be 
reported as well. For radiotherapy in particular, registration of the 
treatment details and information on long-term follow-up should be 
provided to ensure adequate evaluation of the treatment effects.  So 
far, most databases have been initiated by the surgical community or 
generated by for example National Health Services. The underlying 
motive has not so much been development of clinical guidelines, but 
more to implement a clinical auditing system that aims to provide a 
greater level of insight into the process and outcomes of patients who 
undergo medical treatment and to continuously improve this. In order 
to start this improvement cycle (the ‘audit cycle’), it is important to 
identify which quality aspects are important and where improvements 
are required. The most important objective of clinical auditing is to 
initiate a cycle for improvement on a national, regional and local 
level. The feedback that medical specialists are given regarding the 
care that they provide forms the catalyst for improvement initiatives. 
 Several European countries have implemented such audit for 
colorectal cancer, providing much inside in current standards of care. 
It has already resulted in demonstrable improvements in the 
treatment provided to colorectal patients. For example, 
improvements in adequate pre-operative imaging in colon cancer 
patients have been observed, as well as increases in the number of 
patients suffering from rectal carcinoma that were discussed in a 
multidisciplinary team prior to operation. This has resulted in an 
increase of administration of (neo-)adjuvant radiotherapy and an 
improved standard of pathological reporting regarding, for example, 
number of lymph nodes examined and the reporting of circumferential 
resection margins (CRM).  
In addition, results from the population based databases have 
identified the problems concerning frail elderly people. Half of 
patients suffering from bowel cancer are older than 70 years of age. 
Many of these elderly people have comorbidities and are vulnerable to 
both the increased occurrence of complications and the consequences 
thereof. These risks have been definitely confirmed in clinical audits 
and have resulted in awareness that although clinical guidelines 
should be suitable for most patients with a specific condition, 
identification of specific risk groups is warranted. 
In conclusion: clinical auditing is absolutely necessary to evaluate and 
refine clinical guidelines. However, there will always be a need for 
clinical trials to facilitate practice changing research. 
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“Radiomics” refers to the extraction and analysis of advanced 
quantitative imaging features in high throughput from medical 
images, including computed tomography (CT), positron emission 
tomography (PET) and magnetic resonance imaging (MRI) (Lambin et 
al. EJC 2012; ww.radiomics.org). Importantly, these features are 
designed to be extracted from standard-of-care images, leading to a 
very large potential subject pool.  Radiomic data are in a mineable 
form that can be used to build descriptive and predictive models. The 
core hypothesis of radiomics is that these models, which can include 
biological or medical ata, can provide valuable diagnostic, prognostic 
or predictive information.Also, relating image features to phenotypes 
or gene-protein signatures is being investigated. The radiomics 
enterprise can be divided into four processes, each with its own 
challenges that need to be overcome:  (1) image acquisition and 
reconstruction,(2) image segmentation and rendering, (3) feature 
extraction and qualification,(4) bioinformatic analyses. Each step, 
especially involving large datasets,poses unique challenges. The focus 
of this presentation will be on the predictive value of CT & FDG-PET 
radiomics features of non-small cell lung cancer and head and neck 
cancer, complemented by preclinical tumour data. Finally we will 
describe the current and potential applications of radiomics to other 
problems in oncology. 
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Over the past decade the progress in individualized medicine has 
posed major challenges also in radiotherapy of cancer diseases. The 
development of models for decision making seems crucial for taking 
advantage of inter- and intra-patient variability to maximize the 
therapeutic index in RT by increased tumour control and decreased 
normal tissue complications. Models depend to a high degree on 
validated predictors such as the tumour dose-response relationship, 
among many others. 
Using modern RT delivery techniques like IMRT and volumetric arc 
therapy in combination with in-room image-guidance complex dose 
distributions are administered to cover target and spare organs at risk 
with high spatial precision. However, the increasing use of volumetric 
imaging such as cone-beam CT during the fractionated treatment 
course allow for detection of changes in the patient anatomy and, 
thus, detect the temporal aspects in the delivered dose distribution 
which might deviate from the planned one. Utilization of delivered 
dose-response relationships is expected to increase the accuracy of 
prediction models. 
Several aspects are involved in the analysis of the CBCT image sets. 
The inferior image quality due to artefacts compared to conventional 
